Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Company Profile NeonMind Biosciences C.NEON

Alternate Symbol(s):  NMDBF

NeonMind Biosciences Inc is engaged in preclinical research to develop potential clinical treatments and wellness products to address obesity and weight management conditions and to promote health and wellness. The company operates three divisions: a pharmaceutical division engaged in drug development of psychedelic compounds with two lead psilocybin-based drug candidates targeting obesity; a medical services division focused on launching specialty mental health clinics that integrate psychedelic therapeutics into traditional psychotherapy settings; and a consumer products division that currently sells mushroom-infused products to promote health and wellness.


Company Profile & Information (CSE:NEON)

Showcase News Releases

Showcase news

Neovasc Inc.
Neovasc Announces Second Quarter Financial Results and Provides Corporate Update
Argentina Lithium & Energy Corp
Argentina Lithium Closes 1st Tranche of the Non-Brokered Private Placement
Taranis Resources Inc.
Taranis Updates Exploration of South Broadview Conductivity Target and the Status of the Private Placement announced June 28, 2022

More Showcase News Releases »